Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bio-Path Holdings Inc (BPTH)

Bio-Path Holdings Inc (BPTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Bio-Path: Q3 Earnings Snapshot

Bio-Path: Q3 Earnings Snapshot

BPTH : 0.0681 (-2.01%)
Bio-Path: Q2 Earnings Snapshot

Bio-Path: Q2 Earnings Snapshot

BPTH : 0.0681 (-2.01%)
Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum

BPTH : 0.0681 (-2.01%)
Bio-Path Holdings Provides Clinical and Operational Update

BPTH : 0.0681 (-2.01%)
Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025

BPTH : 0.0681 (-2.01%)
Bio-Path: Q1 Earnings Snapshot

Bio-Path: Q1 Earnings Snapshot

BPTH : 0.0681 (-2.01%)
Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

BPTH : 0.0681 (-2.01%)
Bio-Path Holdings Reports Full Year 2024 Financial Results

BPTH : 0.0681 (-2.01%)
Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

BPTH : 0.0681 (-2.01%)
Bio-Path Holdings Expands Global Patent Portfolio

BPTH : 0.0681 (-2.01%)

Barchart Exclusives

These 3 Dividend Aristocrats Look Ready to Rebound in 2026. Should You Buy Them Now?
Three oversold Dividend Aristocrats near recent lows offering reliable income, strong analyst support, and significant upside potential. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar